Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
As I said this business is only going to fail on its disastrous business plan of exclusivity in current markets.
On UK stock market purely for the ease of raising money otherwise Tony 100% would used NZ.
Financially it’s a disaster. They will continue to say all is well but now we see it’s falling apart by the seams.
I explained that the business plan is awful and it still is until they drop prices lower than fever and grab volume. Tony’s brand is good but the direction of exclusivity is the problem. They need to drop expectations and think about surviving. Unfortunately that imo won’t happen.
“NFTs
Posted in: EISB
Posts: 386
Price: 1.225
No Opinion
Few million required3 May 2023 15:25
The issue is funding and nothing to do with any poster stating the obvious. If people are trying to average down be prepared as 2 million now will be more than 50% dilution of the SP.
I am surprised that management have sat on their backsides to raise capital so late here in this market. That’s exactly what happens to others that shut the doors. Too little too late springs to mind here. Protect what you got as managers are not looking out for you here they are looking out for their pet project which was supposed to find cash easy here over on the UK main market!!! Oooops”
Absolutely Ophidian.
What’s even more shocking is the stupidity of the response to your post.
Let’s make it clear.
What Ophidian stated is fact.
Deals inbound so hold onto your hats when this gets released from its shackles.
It’s time many here avoid responding to these multiple deramping thread killers here.
They have one purpose and that it to kill sentiment by spreading doubt in any form to prevent retail buying. This allows the algorithms Bots to work the SP down.
It’s all they are trying to do with these highly retail stocks.
In one way it’s a positive as when the license deal news drops this flies
It is remarkable
This tumour had no response with any treatment previous and potentially had very short time left to live.
A type of tumour not typical for Dox treatment
A tumour that is still shrinking on treatment that if adjusted to the more regular 2 week dosing would have probably now been obliterated.
We now wait to see what will happen on the fortnightly dosing which will be on STS tumours. With patients that haven’t had previous treatments.
Serious game changer. Paradigm shift in chemo for 50 years
You don’t bring it up you state it as opposite to what the CEO has stated will be the line.
You in your manufactured manipulative agenda try to drive a false narrative.
It’s got nothing to do with anyone else but you trying to change what’s has been very very very clearly stated by the CEO
You are doing it to drown out that fact and cause FUD
Oh I wander why that would be!!!
Wyndrum or rather whinging drum 🥁
I will let the company do the talking and your repetition nonsense is overbearing overblown overdone and that is fact.
You are just an agenda maker for your own gain.
You do not know what is going on.
Alastair the CEO is a cool as a cucumber 🥒 and knows what he is doing.
He doesn't say funding is no problem lightly.
He states it because he has multiple avenues from approaches to him over potential positions of which none will be dilutive to SP.
Keep whinging
No
You are creating nonsense.
You are saying your opinion which TBF is very child like repetition to try make adults think you are thick.
The market is bouncing to TA and nothing to do with your stupidity.
The market has a good idea of the company and what is said but when news comes it will trump TA.
You are waisting your time but clearly you have plenty of it in the nursery. Wahh wahh wahhh wahhh
Absolutely not.
You can say and dress up nonsense all day long here as nobody can really stop the stupidity.
Fact AVACTA are funded through best part next year so no extra cash anywhere near required yet when loads of significant news is due anyhow!
Fact Alistair has stated point blankly that there are multiple ways to create cash non diluted to shareholders.
Fact DX could be sold for plus 40mil. This alone will see them through AVA6 phase2 and a lot of runway between with that being the case AVA6k becomes a multi bil pound drug for market. So if they wished later in phase 2 a huge HUGE value licence deal.
Fact they can now out license various lines of direction on AVA6k and also Precision tech for other drugs.
Precision tech now has billions of value in n other directions of use.
They will not be raising cash any other way.
If you say they are or will then you are either just ignorant or a player to cause nonsense.
Plenty of both posting here constantly.
Https://www.trinitydelta.org/wp-content/uploads/2023/12/Avacta-Update-231214.pdf
Massively undervalued at 10% COS
Unbelievable still 10%
😂
Well some people you just cannot help. Well it’s a fairly tiny amount anyhow. Would done well if it had been moved to AVACTA. Chemo without side effects.
Paradigm shift in oncology with a platform proven delivery system precision.
Well you had a chance. See the smiles tomorrow
Let’s clear few points.
DG setup his consulting firm after leaving and flogged it to Oxcillio gaining him 500,000 shares in that company. I don’t remember NFX selling any info to him for the info that was potentially contained within that deal. Also for it then to completely take NXP001 from NFX after initial substantial payment of £50,000 lol back in the days when Kirk and Co flogged it. The only winner was DG.
He has never bought a single share in NFX neither Joanne.
She was supposed to do consulting but did SFA after leaving.
Whole thing stinks and I believe it’s a toxic company hence why industry stays clear and deals never materially happen of any substance.
Directors have had a lovely wedge out of it. Still are. One came back for even more milking the cow as he sidelined off NXP001 to his pals.
Corrupt imo and a lot of half truths told to try milk pi’s
Keep well clear imo.
The FDA (Food and Drug Administration) has several processes in place to expedite the approval of drugs that address unmet medical needs or are intended for serious or life-threatening conditions. These processes aim to ensure that these drugs reach patients in a timely manner while maintaining high safety and efficacy standards.
One such process is the Fast Track designation, which helps accelerate the development and review of drugs that treat serious conditions and fill an unmet medical need. Drugs with Fast Track designation receive more frequent communication and guidance from the FDA, and they may also benefit from expedited review and priority review.
The FDA also offers the Breakthrough Therapy designation, which is granted to drugs that show promising early results in treating serious conditions. This designation provides intensive FDA guidance and involvement in the drug development process, including eligibility for Fast Track designation benefits.
Additionally, the Accelerated Approval process allows the FDA to grant conditional approval to drugs that provide a meaningful benefit over existing treatments for serious conditions. This process is based on surrogate or intermediate endpoints that are reasonably likely to predict clinical benefit, allowing patients to access these drugs while additional data is collected to confirm their effectiveness.
It's important to note that while these processes can expedite drug approvals, the FDA still requires robust evidence of safety and effectiveness before granting full approval. The agency's primary goal is to ensure that drugs benefit patients without compromising their health.
Add to this THE MAIN POINT OF PRECISION AVA6k alone is that it’s using a 40 to 50 year old proven drug. Not a new drug!!!
Therefore RAPID DEVELOPMENT LOW COST TO MARKET.
It’s amazing how slow many of the market watchers are.
It’s NOT 10 plus years. NEW drugs only 1 in 10 successful and cost over a billion each to develop.
Where as redevelopment and enhancement of old proven drugs costs just 10’s millions and AVA6K will most likely get FDA approval in one way or another for faster development.
Accelerated Review is one potential.